Cancer Chemotherapy and Pharmacology

, Volume 58, Supplement 1, pp 55–61

Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

  • Shinya Kimura
  • Tomoko Niwa
  • Kazuko Hirabayashi
  • Taira Maekawa


Imatinib mesylate (Gleevec™) has improved the treatment of Bcr-Abl-positive leukemia. However, resistance is often reported in patients with advanced-stage disease. Chemical modifications of imatinib made with the guidance of molecular modeling have yielded several promising compounds that could override imatinib resistance. Among them, we selected a compound denoted NS-187. The most striking structural characteristic of NS-187 is its trifluoromethyl group at position 3 of the benzamide ring, which strengthens the hydrophobic interactions and fixes the conformation of the compound. NS-187 was 25–55 times more potent than imatinib against wild-type Bcr-Abl in vitro. At physiological concentrations, NS-187 also inhibited the phosphorylation and growth of all Bcr-Abl mutants tested except T315I. In addition to Bcr-Abl, NS-187 also inhibited Lyn, which might be involved in imatinib resistance, without affecting the phosphorylation of Src, Blk, or Yes. This indicates that NS-187 acts as a dual Bcr-Abl/Lyn inhibitor. Our proposed docking models of the NS-187/Abl complex support the notion that NS-187 is more specific for Lyn than for Src. In Balb/c-nu/nu mice, which were injected subcutaneously with Bcr-Abl-positive KU812 cells, NS-187 showed at least tenfold more potency than imatinib. We also tested the ability of NS-187 to suppress tumor growth in another murine tumor model, namely, Balb/c-nu/nu mice intravenously transplanted with BaF3 cells harboring wild-type or several mutations of Bcr-Abl (M244V, G250E, Q252H, Y253F, E255K, T315I, M351T, and H396P). NS-187 prolonged the survival of mice injected with leukemic cells expressing wild-type or all mutated Bcr-Abl except T315I, and its efficacy correlated well with its in vitro effects. NS-187 also inhibited leukemic cells harboring wild-type Bcr-Abl growth in the central nervous system, which sometimes becomes a sanctuary for leukemic cells under imatinib treatment. These results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Bcr-Abl-positive leukemia. A phase I study of NS-187 will start in 2006.


NS-187 INNO-406 Imatinib Chronic myeloid leukemia Bcr-Abl Lyn 


  1. 1.
    Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T (2006) Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 16:1421–1425PubMedCrossRefGoogle Scholar
  2. 2.
    Cary LA, Klinghoffer RA, Sachsenmaier C, Cooper JA (2002) SRC catalytic but not scaffolding function is needed for integrin-regulated tyrosine phosphorylation, cell migration, and cell spreading. Mol Cell Biol 22:2427–2440PubMedCrossRefGoogle Scholar
  3. 3.
    Cortes J, Giles F, O’Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83–86PubMedCrossRefGoogle Scholar
  4. 4.
    Dai Y, Rahmani M, Corey SJ, Dent P, Grant S (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227–34229PubMedCrossRefGoogle Scholar
  5. 5.
    Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830PubMedCrossRefGoogle Scholar
  6. 6.
    Davis ME, Cai H, McCann L, Fukai T, Harrison DG (2003) Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training. Am J Physiol Heart Circ Physiol 284:1449–1453Google Scholar
  7. 7.
    Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653PubMedCrossRefGoogle Scholar
  8. 8.
    Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690–698PubMedCrossRefGoogle Scholar
  9. 9.
    Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMedCrossRefGoogle Scholar
  10. 10.
    Druker BJ (2003) Chronic myeloid leukemia in the imatinib era. Semin Hematol 40(2 Suppl 2):1–3PubMedGoogle Scholar
  11. 11.
    Elefanty AG, Hariharan IK, Cory S (1990) bcr-abl, The hallmark of chronic myeloid leukaemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J 9:1069–1078PubMedGoogle Scholar
  12. 12.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375–381PubMedGoogle Scholar
  13. 13.
    Goldman JM, Melo JV (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464PubMedCrossRefGoogle Scholar
  14. 14.
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880PubMedCrossRefGoogle Scholar
  15. 15.
    Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253PubMedCrossRefGoogle Scholar
  16. 16.
    Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP (2002) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860–1862PubMedCrossRefGoogle Scholar
  17. 17.
    Hochhaus A, La Rosee P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321–1331PubMedCrossRefGoogle Scholar
  18. 18.
    Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254–261PubMedGoogle Scholar
  19. 19.
    Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873–2878PubMedCrossRefGoogle Scholar
  20. 20.
    Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948–3954PubMedCrossRefGoogle Scholar
  21. 21.
    Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2- (6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658–6661PubMedCrossRefGoogle Scholar
  22. 22.
    Naito H, Kimura S, Nakaya Y, Naruoka H, Kimura S, Ito S, Wakayama T, Maekawa T, Hirabayashi K (2006) In vivo inhibitory effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on the proliferation of leukemic cells harbouring Abl kinase domain mutations. Leuk Res 30:1443–1446PubMedCrossRefGoogle Scholar
  23. 23.
    Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236–4243PubMedGoogle Scholar
  24. 24.
    Nardi V, Azam M, Daley GQ (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11:35–43PubMedCrossRefGoogle Scholar
  25. 25.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004Google Scholar
  26. 26.
    O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM (2003) Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98:888–893PubMedCrossRefGoogle Scholar
  27. 27.
    O’Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA III, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ (2004) Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104:2532–2539PubMedCrossRefGoogle Scholar
  28. 28.
    Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K, The Kouseisho Leukemia Study Group (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906–916PubMedGoogle Scholar
  29. 29.
    Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM (2004) Short interfering RNA (siRNA) targeting the lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10:1187–1189PubMedCrossRefGoogle Scholar
  30. 30.
    Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340PubMedCrossRefGoogle Scholar
  31. 31.
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401PubMedCrossRefGoogle Scholar
  32. 32.
    Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517–1536PubMedGoogle Scholar
  33. 33.
    Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R (1996) c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528–531PubMedCrossRefGoogle Scholar
  34. 34.
    Touyz RM, Wu XH, He G, Park JB, Chen X, Vacher J, Rajapurohitam V, Schiffrin EL (2001) Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. J Hypertens 19:441–449PubMedCrossRefGoogle Scholar
  35. 35.
    Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141PubMedCrossRefGoogle Scholar
  36. 36.
    Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B (2002) Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 62:4244–4255PubMedGoogle Scholar
  37. 37.
    Yokota A, Kimura S, Oyama T, Ashihara E, Naito H, Urasaki Y, Ueda T, Terui Y, Hatake K, Hirabayashi K, Maekawa T (2005) Anti-tumor activity of a novel Bcr-Abl/Lyn dual inhibitor, NS-187, in murine CNS Ph+ leukemia models. Blood 106(11 Suppl):148aGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Shinya Kimura
    • 1
  • Tomoko Niwa
    • 2
  • Kazuko Hirabayashi
    • 2
  • Taira Maekawa
    • 1
  1. 1.Department of Transfusion Medicine and Cell TherapyKyoto University HospitalKyotoJapan
  2. 2.Discovery Research LaboratoriesNippon Shinyaku Co. Ltd.KyotoJapan

Personalised recommendations